Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Outperform at Wolfe Research

Wolfe Research upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a peer perform rating to an outperform rating in a report published on Thursday morning, MarketBeat Ratings reports. Wolfe Research currently has $27.00 price target on the biotechnology company’s stock.

A number of other equities analysts have also commented on SRPT. Zacks Research lowered Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Royal Bank Of Canada increased their target price on Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research note on Tuesday, April 7th. Weiss Ratings lowered Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, June 29th. Oppenheimer reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, March 19th. Finally, Citigroup upped their price target on Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a report on Thursday, March 26th. Nine investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and seven have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and a consensus target price of $25.09.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $20.52 on Thursday. The firm has a fifty day simple moving average of $17.79 and a 200-day simple moving average of $19.29. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $25.32. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -21.38, a PEG ratio of 0.21 and a beta of 0.21.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. The business had revenue of $730.80 million for the quarter, compared to analyst estimates of $474.15 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. Sarepta Therapeutics’s revenue was down 1.9% compared to the same quarter last year. During the same period last year, the business posted ($3.42) EPS. On average, sell-side analysts expect that Sarepta Therapeutics will post 3.95 earnings per share for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Sarepta Therapeutics by 9.2% in the 4th quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock valued at $254,167,000 after buying an additional 993,283 shares during the period. AQR Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 454.6% during the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after acquiring an additional 6,390,860 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Sarepta Therapeutics by 107.6% during the 1st quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after acquiring an additional 2,143,211 shares in the last quarter. Erste Asset Management GmbH increased its stake in Sarepta Therapeutics by 1.6% in the fourth quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock valued at $58,727,000 after acquiring an additional 43,000 shares during the period. Finally, Aberdeen Group plc increased its stake in Sarepta Therapeutics by 13.6% in the fourth quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock valued at $48,454,000 after acquiring an additional 268,829 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.